Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cycle Pharmaceuticals

News headline image
Cycle Pharmaceuticals launches CAVHANZA™ (nilotinib) Orally Disintegrating Tablets (ODT), designed for use with PPIs and H₂RAs without food restrictions1
From Cycle Pharmaceuticals
Via Business Wire
News headline image
CAVHANZA™ (nilotinib) Orally Disintegrating Tablets: A New, FDA-approved Treatment Offering PPI and H2RA Flexibility for Ph+ CML Patients1
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Cycle Pharmaceuticals Signs Exclusive U.S. Sales License for PHYRAGO™ (dasatinib) Tablets
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Cycle Pharmaceuticals launches HARLIKU™ (nitisinone) Tablets, the first FDA-approved treatment for use in Alkaptonuria (AKU)
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Cycle Pharmaceuticals’ HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU)
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Cycle Pharmaceuticals Launches Cycle Vita PKU™, an AI-Powered Smartphone App for On-The-Go Management of Phenylketonuria (PKU)
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
From Cycle Pharmaceuticals
Via Business Wire
News headline image
New Drug, TASCENSO ODT® (fingolimod), Launched to Meet the Needs of Multiple Sclerosis Patients in the US Left Without Essential Patient Support
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT® (fingolimod)
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Cycle Pharmaceuticals launches SAJAZIRTM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)
From Cycle Pharmaceuticals
Via Business Wire
News headline image
Cycle Pharmaceuticals Launches Cycle Vita™, a Dedicated Support Platform for Rare Disease Patients
From Cycle Pharmaceuticals
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.